R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Inclusion Criteria: 1. Join the study voluntarily and sign the informed consent; 2. Age ≤ 18 years old ≤75 years old; 3. Expected survival time ≥3 months; 4. Recurrent or refractory diffuse large B-cell lymphoma confirmed by histopathology; 5. Consistent with relapsed or refractory lymphoma: Relapsed lymphoma refers to lymphoma that relapsed after CR obtained from initial chemotherapy. Refractory lymphoma is diagnosed by meeting any of the following criteria: 1) tumor shrinkage \< 50% or progression after 4 courses of chemotherapy prescribed by the standard regimen; 2) CR was achieved by standard chemotherapy, but recurrent within half a year; 3) Relapse for two or more times after CR; 4) Recurrence after hematopoietic stem cell transplantation; 6. There must be at least one evaluable or measurable lesion in line with Lugano2014 criteria: lymph node lesion, the length and diameter of detectable lymph node must be greater than 1.5cm; For non-lymph node lesions, the diameter of extrinsic lesions should be \> 1.0cm; 7. ECOG score 0-2; 8. Bone marrow function: neutrophil count ≥1.5×10\^9/L, platelet count ≥75×10\^9/L, hemoglobin ≥80g/L (neutrophil count ≥1.0×10\^9/L, platelet count ≥50×10\^9/L, hemoglobin ≥75g/L in patients with bone marrow involvement); 9. Liver and kidney function: serum creatinine ≤1.5 times the upper limit of normal value; AST and ALT ≤2.5 times the upper limit of normal value (≤5 times the upper limit of normal value for patients with liver invasion); Total bilirubin ≤1.5 times the upper limit of normal value (≤3 times the upper limit of normal value for patients with liver invasion); Exclusion Criteria: 1. The subject's previous history of antitumor therapy meets one of the following conditions: 1. Previous recipients of mitoxantrone or mitoxantrone liposomes; 2. Prior treatment with doxorubicin or anthracycline with a cumulative dose of doxorubicin \> 360 mg/m2 (1 mg of doxorubicin for other anthracyclines); 3. Patients who had received autologous hematopoietic stem cell transplantation or had received allogeneic hematopoietic stem cell transplantation within 100 days of the first medication; 4. Received anti-tumor therapy (including chemotherapy, targeted therapy, hormone therapy, taking anti-tumor active Chinese medicine, etc.) or participated in other clinical trials and received clinical trial drugs within 4 weeks before the first use of the drug in this study; 2. Hypersensitivity to any investigational drug or its components; 3. Uncontrolled systemic diseases (such as advanced infections, uncontrolled hypertension, diabetes, etc.); 4. Cardiac function and disease conform to one of the following conditions: 1. Long QTc syndrome or QTc interval \>480 ms; 2. Complete left bundle branch block, complete right bundle branch block with left anterior branch block, second degree type II, or third degree atrioventricular block; 3. severe, uncontrolled arrhythmias requiring medical treatment; 4. New York College of Cardiology Grade ≥ III; 5. A history of acute myocardial infarction, unstable angina pectoris, severely unstable ventricular arrhythmias or any other arrhythmia requiring treatment, a history of clinically severe pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction abnormalities within the 6 months prior to recruitment. 5. Hepatitis B and hepatitis C active infection (hepatitis B virus surface antigen positive and hepatitis B virus DNA more than 1x10\^3 copies /mL; HCV RNA over 1x10\^3 copies /mL); 6. Human immunodeficiency virus (HIV) infection (HIV antibody positive); 7. Past or present co-existing malignancies (in addition to non-melanoma basal cell carcinoma of the skin, carcinoma in situ of the breast/cervix, and other malignancies that have been effectively controlled without treatment in the past five years); 8. Primary or secondary central nervous system (CNS) lymphoma or history of CNS lymphoma at the time of recruitment; 9. There is significant gastrointestinal disease at the time of screening that may affect drug intake, transport or absorption (e.g. inability to swallow, chronic diarrhea, intestinal obstruction, etc.); 10. Pregnant and lactating women and patients of childbearing age who do not wish to take contraceptive measures; 11. Situations in which other researchers have determined that participation in this study is not appropriate.